

INFORMAZIONI PERSONALI



Dott. Marcello Fabio Maida

+39.328.7136871

MAIL: marcello.maida@hotmail.it
PEC: marcellofabio.maida.a24g@cl.omceo.it

LinkedIn it.linkedin.com/in/marcellomaida
Skype marcellomaida

Data di nascita 05/03/1984 | Nazionalità Italiana

TITOLO DI STUDIO Medico Chirurgo – Specialista in Gastroenterologia

ISTRUZIONE E TITOLI ACQUISITI

Settembre 2002 – Marzo 2009

Laurea

Laurea in Medicina e Chirurgia presso l'Università degli Studi di Palermo con votazione di 110/110 e lode, conseguita il 26 marzo 2009.

Tesi sperimentale: "L'insulino-resistenza è un fattore di rischio per lo sviluppo di varici esofagee in pazienti con cirrosi epatica HCV correlata".

Aprile 2009 – Luglio 2009

Abilitazione professionale

Abilitazione alla professione di medico-chirurgo conseguita presso l'Università degli Studi di Palermo nella sessione PRIMA dell'anno 2009 con la votazione di 270/270. Codice EMPAM 300 314 392W.

Iscrizione all'Albo dell'Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri della Provincia di Caltanissetta il 27/07/2009, n. CL2688.

Maggio 2010 – Maggio 2015

Specializzazione

Specializzazione in Gastroenterologia, c/o Scuola di Specializzazione in Gastroenterologia dell'Università degli studi di Palermo con la votazione di 50/50 e lode, conseguita il 25 maggio 2015.

Tesi sperimentale: "Predittori di sopravvivenza nei pazienti con epatocarcinoma avanzato dopo la sospensione della terapia con sorafenib". [Tesi pubblicata Hepatology. 2015 Feb 2. doi: 10.1002/hep.27729.]

Gennaio 2017 – Gennaio 2018

Master Universitario

Master Universitario di II livello in "Endoscopia Operativa in età adulta e pediatrica" c/o Università Cattolica del Sacro Cuore di Roma (Direttore Prof. Guido Costamagna), conseguito il 24/01/2018.

Ottobre 2018 – in corso

Abilitazione Scientifica Nazionale

Abilitazione Scientifica Nazionale II Fascia, Settore Concorsuale 06/D4, MALATTIE CUTANEE, MALATTIE INFETTIVE E MALATTIE DELL'APPARATO DIGERENTE.

Validità dal 31/10/2018 al 31/10/2024 (art. 16, comma 1, Legge 240/10).

ESPERIENZA LAVORATIVA

Agosto 2015 – Settembre 2016

Medico specialista con contratto di collaborazione continuativa c/o U.O.C di Gastroenterologia, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo nell'ambito del Progetto di Ricerca Finalizzata RF-2011-02351139 "PHASE IV CLINICAL TRIAL OF ANTI-VIRAL TREATMENT FOR HEPATITIS C INFECTION IN COMPENSATED CIRRHOSIS".

Settembre 2016 – (in corso)

Dirigente Medico c/o U.O.C. di Gastroenterologia, Azienda Ospedaliera Ospedali Riuniti S. Elia-Raimondi, Caltanissetta

POSIZIONI ATTUALI

- Membro del Consiglio Direttivo nazionale della Società Italiana di Gastroenterologia (SIGE)
- Segretario della sezione Sicilia della Società Italiana di Gastroenterologia (SIGE)
- Membro del COVID-19 ad-hoc Committee della World Endoscopy Organization (WEO)
- Membro dell'Author Panel della Cochrane Collaboration

ATTIVITA' SCIENTIFICA

Membro delle seguenti società scientifiche

- European Society of Gastrointestinal Endoscopy (ESGE) 2022
- Società italiana di Gastroenterologia (SIGE) 2013-2022
- Associazione Italiana Gastroenterologi Ospedalieri (AIGO) 2022
- Associazione Giovani Gastroenterologi Italiani (AGGEI) 2015-2022
- Associazione Italiana Studio del Fegato (AISF) 2008-2022

Premi e riconoscimenti per l'attività di ricerca

- Full Bursary AISF annual meeting 2012, 2013 – Roma.
- Full Bursary EASL HCC Summit 2014 – Geneve.
- Full Bursary EASL School of Hepatology 2014 – Amsterdam.
- Full Bursary EASL School of Hepatology 2015 – Barcellona.
- Full Bursary EASL School of Hepatology 2016 – Geneve, Awarded by the course's director for Best Clinical Case Study
- Full Bursary EASL HCC Summit 2017 – Geneve.
- Vincitore della **Borsa di studio FIRE Onlus** finalizzata allo Studio "Rischio di malattie epatiche tra i giovani e gli adolescenti residenti nella regione Lazio a causa dell'abuso di alcolici o di un errato stile di vita: studio epidemiologico e studio d'intervento" – 2015.
- Vincitore della **Borsa di studio AISF "Mario Coppo"** per il progetto di ricerca dal titolo "Ruolo dei meccanismi di immunosorveglianza e morte cellulare programmata nell'incidenza o recidiva di HCC in pazienti con cirrosi epatica da HCV sottoposti a terapia antivirale con DAAs" – 2016.
- Vincitore della **"UEG Visiting Fellowship for Clinicians"** at The Royal Free Hospital and University, London, UK - 2018

Ambiti di ricerca

- Gastrointestinal endoscopy
- Liver cirrhosis (metabolic and viral) and its complications
- HCC (hepatocellular carcinoma)
- Viral chronic liver diseases
- Nonalcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH)
- Autoimmune hepatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis
- Observational studies on chronic liver disease (natural history and epidemiology)
- Drug-induced liver disease and herbal hepatotoxicity

Revisore per le seguenti riviste scientifiche internazionali

JAMA, Gastrointestinal Endoscopy, Journal of Clinical Gastroenterology, UEG Journal, Digestive and Liver Disease, Scientific Reports Nature, Digestive Diseases and Sciences, Journal of Gastrointestinal and Liver Diseases, European Journal of Gastroenterology & Hepatology, Expert Review Anticancer Therapy, BioMed Research International, World Journal of Gastroenterology, World Journal of Hepatology.

Membro del Board editoriale di riviste scientifiche internazionali

BioMed Research International, World Journal of Hepatology.
Membro dell'Author Panel della Cochrane Collaboration.

Indicatori scientometrici (aggiornati a Gennaio 2022)

Google Scholar link: <https://scholar.google.it/citations?user=IPbhwzIAAAAJ&hl=it>
ResearchGate link: https://www.researchgate.net/profile/Marcello_Maida
Web of Science Researcher ID [I-4118-2019](https://orcid.org/0000-0002-4992-9289)
ORCID: <https://orcid.org/0000-0002-4992-9289>

Citazioni complessive: 2523
H-index: 26
i-10 H-index: 43

Publications peer reviewed in PubMed - PMID (PubMed Identifier)

- 1) Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Petta S, Cammà C, Di Marco V, Macaluso FS, **Maida M**, Pizzolanti G, Belmonte B, Cabibi D, Di Stefano R, Ferraro D, Guarnotta C, Venezia G, Craxi A. *Liver Int.* 2011 Apr;31(4):507-15.
- 2) Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: Don't forget the role of cyclosporin. Sinagra E, Orlando A, Renna S, **Maida M**, Cottone M. *Inflamm Bowel Dis.* 2011 Oct 29.
- 3) Causes of and prevention strategies for hepatocellular carcinoma. Cabibbo G, **Maida M**, Genco C, Antonucci M, Cammà C. *Semin Oncol.* 2012 Aug;39(4):374-83.
- 4) Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study Cabibbo G, **Maida M**, Genco C, Parisi P, Peralta P, Antonucci M, Brancatelli G, Cammà C, Craxi A, Di Marco V *World J Hepatol* 2012 September 27; 4(9): 256-261.
- 5) Treatment of hepatocellular carcinoma: present and future. Genco C, Cabibbo G, **Maida M**, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. *Expert Rev Anticancer Ther.* 2013 Apr;13(4):469-79.
- 6) Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist. Macaluso FS, **Maida M**, Alessi N, Cabibbo G, Cabibi D. *World J Hepatol.* 2013 May 27;5(5):288-91.
- 7) Assessment of treatment response in hepatocellular carcinoma: a review of the literature. **Maida M**, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. *Future Oncol.* 2013 Jun;9(6):845-54.
- 8) Progressive multi-organ expression of immunoglobulin G4-related disease: A case report. **Maida M**, Macaluso FS, Cabibbo G, Lo Re G, Alessi N. *World J Hepatol.* 2013 Jun 27;5(6):336-9.
- 9) Hepatobiliary and Pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis. Macaluso F, **Maida M**, Burgio MD, Brancatelli G. *J Gastroenterol Hepatol.* 2013 Aug;28(8):1257.
- 10) Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response. Cabibbo G, **Maida M**, Genco C, Alessi N, Peralta M, Butera G, Galia M, Brancatelli G, Genova C, Raineri M, Orlando E, Attardo S, Giarratano A, Midiri M, Di Marco V, Craxi A, Cammà C. *PLoS One.* 2013 Jul 29;8(7):e70016. doi: 10.1371/journal.pone.0070016. Print 2013.
- 11) Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. Macaluso FS, **Maida M**, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. *BioMed Research International* 2013 <http://dx.doi.org/10.1155/2013/564645>.
- 12) Imaging appearance of treated hepatocellular carcinoma. Agnello F, Salvaggio G, Cabibbo G, **Maida M**, Lagalla R, Midiri M, Brancatelli G. *World J Hepatol.* 2013 Aug 27;5(8):417-24. doi: 10.4254/wjh.v5.i8.417.
- 13) Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients with Chronic HCV Genotype 1 Infection. Macaluso FS, **Maida M**, Cammà C, Cabibi D, Alessi N, Cabibbo G, Di Marco V, Craxi A, Petta S. *Clin Gastroenterol Hepatol.* 2013 Oct 7. pii: S1542-3565(13)01507-3.

- 14) Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Cabibbo G, **Maida M**, Cammà C, Craxì A. *Expert Rev Anticancer Ther.* 2013 Dec;13(12):1355-61. doi: 10.1586/14737140.2013.859989. Epub 2013 Nov 13.
- 15) Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. Licata A, **Maida M**, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, Almasio PL. *World J Hepatol.* 2013 Dec 27;5(12):685-91. doi: 10.4254/wjh.v5.i12.685.
- 16) Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. **Maida M**, Macaluso FS, Galia M, Cabibbo G. *World J Hepatol.* 2013 Dec 27;5(12):696-700. doi: 10.4254/wjh.v5.i12.696.
- 17) Staging systems of hepatocellular carcinoma: A review of literature. **Maida M**, Orlando E, Cammà C, Cabibbo G. *World J Gastroenterol.* 2014 Apr 21;20(15):4141-4150.
- 18) Steatosis Affects the Performance of Liver Stiffness Measurement for Fibrosis Assessment in Patients with Genotype 1 Chronic Hepatitis C. Macaluso FS, **Maida M**, Cammà C, Cabibbo G, Cabibi D, Alduino R, Marco VD, Craxì A, Petta S. *J Hepatol.* 2014 Sep;61(3):523-9. doi: 10.1016/j.jhep.2014.04.045. Epub 2014 May 9.
- 19) Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. Licata A, **Maida M**, Cabibi D, Butera G, Macaluso FS, Alessi N, Caruso C, Craxì A, Almasio PL. *Dig Liver Dis.* 2014 Sep 12. pii: S1590-8658(14)00660-4. doi: 10.1016/j.dld.2014.08.040.
- 20) Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Iavarone M, Cabibbo G, Biolato M, Corte CD, **Maida M**, Barbàra M, Basso M, Vavassori S, Craxì A, Grieco A, Cammà C, Colombo M. *Hepatology.* 2015 Feb 2. doi: 10.1002/hep.27729.
- 21) The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Petta S, **Maida M**, Macaluso FS, Marco VD, Cammà C, Cabibi D, Craxì A. *Hepatology.* 2015 Apr 9. doi: 10.1002/hep.27844. [Epub ahead of print].
- 22) TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. Petta S, **Maida M**, Grimaudo S, Pipitone RM, Macaluso FS, Cabibi D, Cammà C, Di Marco V, Sferrazza S, Craxì A. *Liver Int.* 2015 Jul 17. doi: 10.1111/liv.12918. [Epub ahead of print]
- 23) Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. **Maida M**, Iavarone M, Raineri M, Cammà C, Cabibbo G. *World J Hepatol.* 2015 Aug 18;7(17):2053-7. doi: 10.4254/wjh.v7.i17.2053.
- 24) Hepatitis C Virus Infection is Associated With Increased Cardiovascular Mortality: A Meta-analysis of Observational Studies. Petta S, **Maida M**, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. *Gastroenterology.* 2015 Sep 16. pii: S0016-5085(15)01322-0.
- 25) Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. Cabibbo G, Petta S, **Maida M**, Cammà C. *Dig Dis.* 2015 Sep;33(5):668-74. doi: 10.1159/000438477.
- 26) Genetic background in nonalcoholic fatty liver disease: A comprehensive review. Macaluso FS, **Maida M**, Petta S. *World J Gastroenterol.* 2015 Oct 21;21(39):11088-111.

- 27) Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, **Maida M**, Attardo S, Pettinari I, Pinna AD, Golfieri R. *Liver Int.* 2015 Nov 25. doi: 10.1111/liv.13029.
- 28) Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, **Maida M**, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group. *Aliment Pharmacol Ther.* 2015 Dec 14. doi: 10.1111/apt.13485. [Epub ahead of print]
- 29) Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. Cabibi D, Bronte F, Porcasi R, Ingraio S, Giannone AG, **Maida M**, Grazia Bavetta M, Petta S, Di Marco V, Calvaruso V. *Anal Cell Pathol (Amst).* 2015;2015:431750. doi: 10.1155/2015/431750. Epub 2015 Nov 17.
- 30) Years of life that could be saved from prevention of hepatocellular carcinoma. Cucchetti A, Trevisani F, Bucci L, Ravaioli M, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, **Maida M**, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Pinna AD; Italian Liver Cancer (ITA.LI.CA) group; Italian Liver Cancer ITA LI CA group. *Aliment Pharmacol Ther.* 2016 Apr;43(7):814-24. doi: 10.1111/apt.13554. Epub 2016 Feb 11.
- 31) Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma. **Maida M**, Macaluso FS, Valenza F, Virdone R. *J Gastrointest Liver Dis.* 2016 Jun;25(2):253-5.
- 32) Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. Renna S, Orlando E, Macaluso FS, **Maida M**, Affronti M, Giunta M, Sapienza C, Rizzuto G, Orlando R, Dimarco M, Cottone M, Orlando A. *Aliment Pharmacol Ther.* 2016 Aug;44(3):310-1.
- 33) Non-invasive assessment of liver injury in non-alcoholic fatty liver disease: a review of literature. **Maida M**, Macaluso FS, Salomone F, Petta *Curr Mol Med.* 2016 Oct 4. [Epub ahead of print]
- 34) Screening and surveillance for hepatocellular carcinoma: perspective of a new era? **Maida M**, Malizia G, Affronti A, Virdone R, Maida C, Margherita V, D'Amico G. *Screening Expert Rev Anticancer Ther.* 2016 Oct 12. [Epub ahead of print]
- 35) Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. Almasio PL, Licata A, **Maida M**, Macaluso FS, Costantino A, Alessi N, Grimaudo S, Accardi G, Caruso C, Craxi A. *Hepat Mon.* 2016 Oct 16;16(11):e31681.
- 36) Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF- α inhibitors and conventional immunosuppressants. Macaluso FS, **Maida M**, Renna S, Orlando E, Affronti M, Sapienza C, Dimarco M, Orlando R, Rizzuto G, Cottone M, Orlando A. *Dig Liver Dis.* 2016 Oct 14. pii: S1590-8658(16)30747-2. doi: 10.1016/j.dld.2016.10.001. [Epub ahead of print]
- 37) Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Macaluso FS, Renna S, **Maida M**, Dimarco M, Sapienza C, Affronti M, Orlando E, Rizzuto G, Orlando R, Ventimiglia M, Cottone M, Orlando A. *Scand J Gastroenterol.* 2017 May 29:1-7.
- 38) Radiofrequency Ablation for Treatment of Refractory Gastric Antral Vascular Ectasia: A Systematic Review of the Literature. **Maida M**, Camilleri S, Manganaro M, Garufi S, Scarpulla G. *Gastroenterol Res Pract.* 2017;2017:5609647. doi: 10.1155/2017/5609647.

- 39) Screening of colorectal cancer: present and future. **Maida M**, Macaluso FS, Ianiro G, Mangiola F, Sinagra E, Hold G, Maida C, Cammarota G, Gasbarrini A, Scarpulla G. *Expert Rev Anticancer Ther.* 2017 Oct 12. doi: 10.1080/14737140.2017.1392243.
- 40) New endoscopy advances to refine adenoma detection rate for colorectal cancer screening: None is the winner. **Maida M**, Camilleri S, Manganaro M, Garufi S, Scarpulla G. *World J Gastrointest Oncol.* 2017 Oct 15;9(10):402-406.
- 41) Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, De Santis A, Corte CD, **Maida M**, Attili AF, Sangiovanni A, Cammà C, La Torre G, Gasbarrini A, Grieco A. *Ann Hepatol.* 2017 Dec 27;17(1):110-118. doi: 10.5604/01.3001.0010.7542.
- 42) Faecal Microbiota Transplantation as Emerging Treatment in European Countries. **Maida M**, McIlroy J, Ianiro G, Cammarota G. *Adv Exp Med Biol.* 2018;1050:177-195. doi: 10.1007/978-3-319-72799-8_11.
- 43) Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact? **Maida M**, Cabibbo G, Cammà C. *Expert Rev Anticancer Ther.* 2018 Feb 21. doi: 10.1080/14737140.2018.1443814.
- 44) Binge Drinking among adolescents is related to the development of Alcohol Use Disorders: results from a Cross-Sectional Study. Addolorato G, Vassallo GA, Antonelli G, Antonelli M, Tarli C, Mirijello A, Agyei-Nkansah A, Mentella MC, Ferrarese D, Mora V, Barbara M, **Maida M**, Cammà C, Gasbarrini A; Alcohol Related Disease Consortium. *Sci Rep.* 2018 Aug 22;8(1):12624. doi: 10.1038/s41598-018-29311-y.
- 45) Efficacy of different faecal microbiota transplantation protocols for *Clostridium difficile* infection: A systematic review and meta-analysis. Ianiro G, **Maida M**, Burisch J, Simonelli C, Hold G, Ventimiglia M, Gasbarrini A, Cammarota G. *United European Gastroenterol J.* 2018 Oct;6(8):1232-1244. doi: 10.1177/2050640618780762. Epub 2018 Jun 3.
- 46) Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. Macaluso FS[§], **Maida M**[§], Ventimiglia M, Renna S, Cottone M, Orlando A. *Inflamm Bowel Dis.* 2018 Dec 22. doi: 10.1093/ibd/izy365.
- 47) Quality measures improving endoscopic screening of colorectal cancer: a review of the literature. **Maida M**, Morreale G, Sinagra E, Ianiro G, Margherita V, Cirrone Cipolla A, Camilleri S. *Expert Rev Anticancer Ther.* 2019 Jan 7. doi: 10.1080/14737140.2019.1565999.
- 48) Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? Cabibbo G, Rossi M, Celsa C, **Maida M**, Cammà C. *Recenti Prog Med.* 2018 Dec;109(12):605-608. doi: 10.1701/3082.30746.
- 49) Safety of NER1006. **Maida M**. *Gastrointest Endosc.* 2019 Sep;90(3):540-541. doi: 10.1016/j.gie.2019.04.213.
- 50) Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease in Real-life Experiences: A Meta-analysis of Observational Studies. Macaluso FS[§], **Maida M**[§], Ventimiglia M, Cottone M, Orlando A. *Expert Opin Biol Ther.* 2019 Dec 20.
- 51) Incidence of hepatocellular carcinoma after HCV eradication: assessing the risk. **Maida M**, Macaluso FS. *Hepatobiliary Surg Nutr.* 2020;9(2):255-256. doi:10.21037/hbsn.2019.10.17
- 52) Current challenges and future needs of clinical and endoscopic training in gastroenterology: a European survey. **Maida M**, Alrubaiy L, Bokun T, Bruns T, Castro V, China L, Conroy G, Trabulo

- D, Van Steenkiste C, Voermans RP, Burisch J, Ianiro G. *Endosc Int Open*. 2020 Apr;8(4):E525-E533. doi: 10.1055/a-1093-0877. Epub 2020 Mar 23.
- 53) Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study. **Maida M**, Sinagra E, Morreale GC, Sferrazza S, Scalisi G, Schillaci D, Ventimiglia M, Macaluso FS, Vettori G, Conoscenti G, Di Bartolo C, Garufi S, Catarella D, Manganaro M, Virgilio CM, Camilleri S. *World J Gastroenterol*. 2020 Apr 28;26(16):1950-1961. doi: 10.3748/wjg.v26.i16.1950.
- 54) Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: a national survey. **Maida M**, Sferrazza S, Savarino E, Ricciardiello L, Repici A, Morisco F, Furnari M, Fuccio L, Morreale GC, Vitello A, Burra P, Marchi S, Annibale B, Benedetti A, Alvaro D, Ianiro G; Italian Society of Gastroenterology (SIGE). *Dig Liver Dis*. 2020 May 16. doi: 10.1016/j.dld.2020.05.017. Online ahead of print.
- 55) Tenapanor for the treatment of irritable bowel syndrome with constipation. Sinagra E, Rossi F, Raimondo D, Conoscenti G, Anderloni A, Guarnotta V, **Maida M**. *Expert Rev Clin Pharmacol*. 2020;1-7. doi:10.1080/17512433.2020.1762570.
- 56) Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey. Marasco G, Nardone OM, **Maida M**, Boskoski I, Pastorelli L, Scaldaferrri F; Italian Association of Young Gastroenterologist and Endoscopist (AGGEI). *Dig Liver Dis*. 2020 May 23:S1590-8658(20)30233-4. doi: 10.1016/j.dld.2020.05.023. Epub ahead of print. PMID: 32507619
- 57) Management of antiplatelet or anticoagulant therapy in endoscopy: A review of literature. **Maida M**, Sferrazza S, Maida C, Morreale GC, Vitello A, Longo G, Garofalo V, Sinagra E. *World J Gastrointest Endosc*. 2020 Jun 16;12(6):172-192. doi: 10.4253/wjge.v12.i6.172. PMID: 32843928; PMCID: PMC7415229.
- 58) Effectiveness and safety of NER1006 versus standard bowel preparations: A meta-analysis of randomized phase-3 clinical trials. **Maida M**, Macaluso FS, Sferrazza S, Ventimiglia M, Sinagra E. *Dig Liver Dis*. 2020;S1590-8658(20)30252-8. doi:10.1016/j.dld.2020.05.046. [published online ahead of print, 2020 Jun 22].
- 59) New Therapeutic Molecules and their Metabolism in Gastroenterology. Nakov R, **Maida M**, Ianiro G. *Curr Drug Metab*. 2020;21(4):246. doi:10.2174/138920022104200615111932.
- 60) Screening of gastrointestinal cancers during COVID-19: a new emergency. **Maida M**. *Lancet Oncol*. 2020;21(7):e338. doi:10.1016/S1470-2045(20)30341-7.
- 61) Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. Vitello A, Shahini E, Macaluso FS, Morreale GC, Sinagra E, Pallio S, **Maida M**. *Expert Rev Anticancer Ther*. 2020 Aug 18. doi: 10.1080/14737140.2020.1813030. Epub ahead of print. PMID: 32811225.
- 62) GI Training in the COVID-19 Era: A Problem of Global Concern. Marasco G, **Maida M**. *Dig Dis Sci*. 2020;10.1007/s10620-020-06578-8. doi:10.1007/s10620-020-06578-8.
- 63) Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature. Rogger TM, Michielan A, Sferrazza S, Pravadelli C, Moser L, Agugiaro F, Vettori G, Seligmann S, Merola E, **Maida M**, Ciarleglio FA, Brolese A, de Pretis G. *World J Gastroenterol*. 2020 Sep 21;26(35):5375-5386. doi: 10.3748/wjg.v26.i35.5375.
- 64) Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. Furnari M, Eusebi LH, Savarino E, Petruzzellis C, Esposito G, **Maida M**, Ricciardiello L, Pecere S, Buda A, De Bona M, Spada C, Di Giulio E, Costamagna G, Boskoski I,

Giannini EG; Young-ENDO-ITA Study Group. Gut. 2020 Sep 28;gutjnl-2020-323116. doi: 10.1136/gutjnl-2020-323116. Epub ahead of print. PMID: 32989018; PMCID: PMC7523174.

65) Use of artificial intelligence in improving adenoma detection rate during colonoscopy: Might both endoscopists and pathologists be further helped. Sinagra E, Badalamenti M, **Maida M**, Spadaccini M, Maselli R, Rossi F, Conoscenti G, Raimondo D, Pallio S, Repici A, Anderloni A. World J Gastroenterol. 2020 Oct 21;26(39):5911-5918. doi: 10.3748/wjg.v26.i39.5911. PMID: 33132644.

66) Effectiveness and tolerability of very-low volume preparation for colonoscopy: a narrative review. Sinagra E, Sferrazza S, Vitello A, Morreale G, Rossi F, Conoscenti G, Pallio S, Raimondo D, **Maida M**. Curr Drug Metab. 2020 Dec 8. doi: 10.2174/1389200221999201208212007. Epub ahead of print. PMID: 33292108.

67) An infection rate stratified, algorithm guided, multiple-level, continuously pooled testing strategy. Gu T, Yao L, Meng X, Graff JC, Thomason D, Li J, Dong W, Jiao Y, Aleya L, **Maida M**, Wang CY, Zangerl B, Genini S, Ray K, Goldman E, Ji J, Alexandrov AV, Sun D, Gu W, Wang Y. A cost-effective plan for global testing. Sci Total Environ. 2020 Dec 24;765:144251. doi: 10.1016/j.scitotenv.2020.144251. Epub ahead of print. PMID: 33387925.

68) Effectiveness and safety of underwater techniques in gastrointestinal endoscopy: a comprehensive review of the literature. Maida M, Sferrazza S, Murino A, Lisotti A, Lazaridis N, Vitello A, Fusaroli P, de Pretis G, Sinagra E. Surg Endosc. 2021 Jan;35(1):37-51. doi: 10.1007/s00464-020-07907-8. Epub 2020 Aug 27. PMID: 32856154.

69) Could Chronic Idiopathic Intestinal Pseudo-Obstruction Be Related to Viral Infections? Sinagra E, Pellegatta G, **Maida M**, Rossi F, Conoscenti G, Pallio S, Alloro R, Raimondo D, Anderloni A. J Clin Med. 2021 Jan 13;10(2):E268. doi: 10.3390/jcm10020268. PMID: 33450988.

70) COVID-19 vaccine: Call for employees in international transportation industries and international travelers as the first priority in global distribution. Yu Z, Wang G, Goldman E, Zangerl B, Xie N, Cao Y, Chen J, Day SW, Howard SC, **Maida M**, Ray K, Jablonski MM, Ji J, Postlethwaite A, Gu W, Sun D, Aleya L. Open Med (Wars). 2021 Jan 11;16(1):134-138. doi: 10.1515/med-2021-0210. PMID: 33521319; PMCID: PMC7811367.

71) New Therapeutic Molecules and their Metabolism in Gastroenterology- Part II. Nakov R, **Maida M**, Ianiro G. Curr Drug Metab. 2021;22(2):84. doi: 10.2174/138920022202210302103413. PMID: 33783341.

72) Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. **Maida M**, Morreale GC, Sferrazza S, Sinagra E, Scalisi G, Vitello A, Vettori G, Rossi F, Catarella D, Di Bartolo CE, Schillaci D, Raimondo D, Camilleri S, Orlando A, Macaluso FS. Dig Liver Dis. 2021 May 11;S1590-8658(21)00163-8. doi: 10.1016/j.dld.2021.04.006. Epub ahead of print. PMID: 33994129.

73) Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Macaluso FS, **Maida M**, Grova M, Crispino F, Teresi G, Orlando A, Orlando A. Therap Adv Gastroenterol. 2021 May 3;14:17562848211010668. doi: 10.1177/17562848211010668. PMID: 33995582; PMCID: PMC8111554.

74) Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. Macaluso FS, **Maida M**, Ventimiglia M, Orlando A. Dig Liver Dis. 2021 May 16;S1590-8658(21)00203-6. doi: 10.1016/j.dld.2021.04.018. Epub ahead of print. PMID: 34011482.

- 75) Young gastrointestinal angle. E-learning in gastroenterology: Future is now. **Maida M**, Cammà C. *United European Gastroenterol J*. 2021 May 26. doi: 10.1002/ueg2.12091. Epub ahead of print. PMID: 34038629.
- 76) Blood-based prognostic biomarkers in Crohn's patients on biologics: a promising tool to predict endoscopic outcomes. Crispino F, Grova M, **Maida M**, Renna S, Mocciaro F, Casà A, Rizzuto G, Tesè L, Scimeca D, Di Mitri R, Macaluso FS, Orlando A. *Expert Opin Biol Ther*. 2021 May 27. doi: 10.1080/14712598.2021.1935857. Epub ahead of print. PMID: 34042009.
- 77) Digital single-operator cholangioscopy in treating difficult biliary stones: results from a multicenter experience. Pallio S, Sinagra E, Santagati A, D'Amore F, Rossi F, Conoscenti G, Romeo F, Borina E, Bellerone R, **Maida M**, Alloro R, Tarantino I, Raimondo D. *Minerva Gastroenterol*. 2021 Jul 9. doi: 10.23736/S2724-5985.21.02892-8. Epub ahead of print. PMID: 34240591.
- 78) Digital single-operator cholangioscopy in treating difficult biliary stones: results from a multicenter experience. Pallio S, Sinagra E, Santagati A, D'Amore F, Rossi F, Conoscenti G, Romeo F, Borina E, Bellerone R, **Maida M**, Alloro R, Tarantino I, Raimondo D. *Minerva Gastroenterol (Torino)*. 2021 Jul 9. doi: 10.23736/S2724-5985.21.02892-8. Epub ahead of print. PMID: 34240591.
- 79) Microbiota Gut-Brain Axis in Ischemic Stroke: A Narrative Review with a Focus about the Relationship with Inflammatory Bowel Disease. Sinagra E, Pellegatta G, Guarnotta V, **Maida M**, Rossi F, Conoscenti G, Pallio S, Alloro R, Raimondo D, Pace F, Anderloni A. *Life (Basel)*. 2021 Jul 19;11(7):715. doi: 10.3390/life11070715. PMID: 34357086; PMCID: PMC8305026.
- 80) Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. Marasco G, **Maida M**, Morreale GC, Licata M, Renzulli M, Cremon C, Stanghellini V, Barbara G. *Can J Gastroenterol Hepatol*. 2021 Sep 1;2021:2534975. doi: 10.1155/2021/2534975. PMID: 34513750; PMCID: PMC8429023.
- 81) Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, **Maida M**, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis*. 2021 Sep 16:S1590-8658(21)00761-1. doi: 10.1016/j.dld.2021.08.020. Epub ahead of print. PMID: 34538764.
- 82) Upper gastrointestinal tract involvement in Crohn's disease: A relevant yet underestimated problem. **Maida M**, Macaluso FS, Orlando A. *Dig Liver Dis*. 2021 Sep 27:S1590-8658(21)00775-1. doi: 10.1016/j.dld.2021.09.006. Epub ahead of print. PMID: 34593347.
- 83) Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease. Macaluso FS, Cappello M, Crispino F, Grova M, Privitera AC, Piccillo G, Magnano A, Ferracane C, Belluardo N, Giangreco E, Fries W, Viola A, Di Mitri R, Mocciaro F, Camilleri S, Garufi S, Renna S, Casà A, **Maida M**, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). *Dig Liver Dis*. 2021 Dec 16:S1590-8658(21)00887-2. doi: 10.1016/j.dld.2021.11.021. Epub ahead of print. PMID: 34924320.
- 84) Definition of a hospital volume threshold to optimize outcomes after drainage of pancreatic fluid collections with lumen-apposing metal stents: a nationwide cohort study. Facciorusso A, Amato A, Crinò SF, Sinagra E, **Maida M**, Fugazza A, Binda C, Coluccio C, Repici A, Anderloni A, Tarantino I, Fabbri C; i-EUS Group. *Gastrointest Endosc*. 2021 Dec 18:S0016-5107(21)01885-X. doi: 10.1016/j.gie.2021.12.006. Epub ahead of print. PMID: 34932991.
- 85) An Unusual Presentation of Crohn's Disease Diagnosed Following Accidental Ingestion of Fruit Pits: Report of Two Cases and Review of the Literature. Sinagra E, Raimondo D, Iacopinelli

SM, Rossi F, Conoscenti G, Di Maggio MA, Testai S, Alloro R, Marasà M, Calandra A, Costanza C, Cristofalo S, Pallio S, **Maida M**, Tarantino I, Arena G. *Life (Basel)*. 2021 Dec 16;11(12):1415. doi: 10.3390/life11121415. PMID: 34947946.

86) Surveillance strategies for precancerous gastric conditions after *Helicobacter pylori* eradication: There is still need for a tailored approach. Shahini E, **Maida M**. *World J Gastroenterol*. 2021 Dec 14;27(46):8033-8039. doi: 10.3748/wjg.v27.i46.8033. PMID: 35046629; PMCID: PMC8678819.

87) EUS-guided choledochoduodenostomy for malignant distal biliary obstruction after failed ERCP: a retrospective nationwide analysis. Fugazza A, Fabbri C, Di Mitri R, Petrone MC, Colombo M, Cugia L, Amato A, Forti E, Binda C, **Maida M**, Sinagra E, Repici A, Tarantino I, Anderloni A; i-EUS Group, Donato G, de Nucci G, Manno M, Pollino V, Macchiarelli R, Leone N, Badas R, Lovera M, Armellini E, Redaelli A, Mangiavillano B, Brancaccio ML, Attili F, Togliani T, Aragona G, Khalaf K, Conte E. *Gastrointest Endosc*. 2022 Jan 4:S0016-5107(21)01946-5. doi: 10.1016/j.gie.2021.12.032. Epub ahead of print. PMID: 34995640.

88) Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience. Grova M, Crispino F, **Maida M**, Renna S, Mannino M, Casà A, Rizzuto G, Macaluso FS, Orlando A. *Eur J Gastroenterol Hepatol*. 2022 Jan 31. doi: 10.1097/MEG.0000000000002348. Epub ahead of print. PMID: 35102111.

Publications peer reviewed in PubMed - PMID (PubMed Identifier) Listed as collaborator

89) Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Pecorelli A, Lenzi B, Gramenzi A et al; Italian LiverCancer (ITA.LI.CA) group. *Liver Int*. 2017 Mar;37(3):423-433. doi: 10.1111/liv.13242. Epub 2016 Oct 2.

90) The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Bucci L, Garuti F, Lenzi B et al; Italian Liver Cancer (ITA.LI.CA) group. *Liver Int*. 2017 Feb;37(2):259-270.

91) Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S. HCC-NAFLD Italian Study Group. *Hepatology*. 2016 Mar;63(3):827-38. doi: 10.1002/hep.28368. Epub 2016 Jan 14.

92) Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. Sacco R, Mismas V, Granito A, Musettini G, Masi G, Caparello C, Vivaldi C, Felder M, Bresci G, Fornaro L; Italian Liver Cancer (IT.LI.CA) group. *Int J Biol Markers*. 2015 Feb 24;30(1):e65-72.

93) Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. Vitale A, Burra P, Frigo AC et al; Italian Liver Cancer (ITA.LI.CA) group. *J Hepatol*. 2015 Mar;62(3):617-24.

94) Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. Cucchetti A, Trevisani F, Pecorelli A et al; Italian Liver Cancer Group. *J Hepatol*. 2014 Aug;61(2):333-41.

95) Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Cabibbo G, Petta S, Calvaruso et al.

Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Aliment Pharmacol Ther. 2017 Aug 9. doi: 10.1111/apt.14256.

96) Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davi A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxi A, Di Marco V; Rete Sicilia Selezione Terapia–HCV (RESIST-HCV). Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30441-4. doi: 10.1053/j.gastro.2018.04.008.

COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	C1	C1	C1	C1	C1
Spagnolo	B1	B1	B1	B1	A2

Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato
 Quadro Comune Europeo di Riferimento delle Lingue

CAPACITA' E COMPETENZE INFORMATICHE

ECDL (European Computer Driving Licence) conseguita nel 2000.

Sistemi operativi: Mac OSX, Microsoft: MS-DOS, Windows '95-98-ME, 2000, XP, Vista, 7, 8,
Software: Microsoft Word, Power Point, Excel, Access, Adobe Photoshop, Safari, Internet Explorer.
Software di statistica: (SPSS; RevMan; MedCalc)

Il sottoscritto è consapevole che in caso di dichiarazioni non veritiere, di formazione o uso di atti falsi verrà punito ai sensi del Codice Penale e delle Leggi speciali in materia così come previsto dall'art. 76 del D.P.R. n. 445/2000 e che, inoltre, qualora dal controllo effettuato emerga la non veridicità del contenuto delle dichiarazioni rese, decadrà dai benefici eventualmente conseguenti al provvedimento emanato sulla base della dichiarazione non veritiera – art. 75 del D.P.R. n. 445/2000. Il sottoscritto autorizza il trattamento dei propri dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"

Caltanissetta, 02/02/2022

